Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial

References

• WagnerADGrotheWHaertingJKleberGGrotheyAFleigWEChemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate dataJ Clin Oncol200624182903290916782930
   PubMed Web of Science ®Google Scholar
• KangJHLeeSILim doHSalvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care aloneJ Clin Oncol201230131513151822412140
   PubMed Web of Science ®Google Scholar
• FordHEMarshallABridgewaterJACOUGAR-02 InvestigatorsDocetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialLancet Oncol2014151788624332238
   PubMed Web of Science ®Google Scholar
• Thuss-PatiencePCKretzshmarABichevDSurvival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Eur J Cancer201147152306231421742485
   PubMed Web of Science ®Google Scholar
• BangYJVan CutsemEFetereislovaAToGA Trial InvestigatorsTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER-2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• WilkeHMuroKCutsemERamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• SatohTXuRHChungHCLapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN – a randomized, phase III studyJ Clin Oncol201432192039204924868024
   PubMed Web of Science ®Google Scholar
• CareyNLa ThangueNBHistone deacetylase inhibitors: gathering paceCur Opin Pharmacol200664369375
   PubMed Web of Science ®Google Scholar
• SuzukiTYokozakiHKuniyasuHEffect of trichostatin A on cell growth and expression of cell cycle-and apoptosis-related molecules in human gastric and oral carcinoma cell linesInt J Cancer200088699299711093826
   PubMed Web of Science ®Google Scholar
• ZhangXYashiroMRenJHirakawaKHistone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell linesOncol Rep200616356356816865256
   PubMed Web of Science ®Google Scholar
• GöttlicherMMinucciSZhuPValproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cellsEMBO J200120246969697811742974
   PubMed Web of Science ®Google Scholar
• HrzenjakAMoinfarFKremserMLValproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cellsMol Cancer Ther2006592203221016985053
   PubMed Web of Science ®Google Scholar
• RocchiPTonelliRCamerinCp21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cellsOncol Rep20051361139114415870934
   PubMed Web of Science ®Google Scholar
• YuXGuoZSMarcuMGModulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228J Natl Cancer Inst200294750451311929951
   PubMed Web of Science ®Google Scholar
• BlagosklonnyMVRobeyRSackettDLHistone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicityMol Cancer Ther200211193794112481415
   PubMed Web of Science ®Google Scholar
• CatalanoMGPoliRPuglieseMFortunatiNBoccuzziGValproic acid enhances tubulin acetylation and apoptoic activity of paclitaxel on anaplastic thyroid cancer cell linesEndocr Relat Cancer200714383984517914112
   PubMed Web of Science ®Google Scholar
• YagiYFushidaSHaradaSEffects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell lineJ Exp Clin Cancer Res20102914921080974
   PubMed Web of Science ®Google Scholar
• BarkerCABishopAJChangMBealKChanTAValproic acid use during radiation therapy for glioblastoma associated with improved survivalInt J Radiat Oncol Biol Phys201386350450923523186
   PubMed Web of Science ®Google Scholar
• HironakaSZendaSBokuNFukutomiAYoshinoTOnozawaYWeekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancerGastric Cancer20069141816557431
   PubMedGoogle Scholar
• HironakaSUedaSYasuiHRandomized open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trialJ Clin Oncol201331354438444424190112
   PubMed Web of Science ®Google Scholar
• FushidaSKajiMOyamaKRandomized phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancerOnco Targets Ther2015893994125960665
   PubMed Web of Science ®Google Scholar
• PhielCJZhangFHuangEYGuentherMGLazarMAKleinPSHistone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogenJ Biol Chem200127639367343674111473107
   PubMed Web of Science ®Google Scholar
• AraiTHamaguchiTShiraoKWeekly paclitaxel in patients with heavily treated advanced gastric cancerProc Am Soc Clin Oncol200322supplabstr 1291321
   Google Scholar
• KuendgenAStruppCAivadoMTreatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acidBlood20041041266126915155466
   PubMed Web of Science ®Google Scholar
• SorianoAOYangHFaderlSSafety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeBlood200711072302230817596541
   PubMed Web of Science ®Google Scholar
• Gracia-ManeroGKantarjianHMSanchez-GonzalezBPhase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood2006108103271327916882711
   PubMed Web of Science ®Google Scholar
• IssaJPGracia-ManeroGHuangXResults of phase II randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemiaCancer2015121455656125336333
   PubMed Web of Science ®Google Scholar
• Fayyad-KazanHRouasRMerimiMValproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylaseJ Biol Chem201028527204812049120427269
   PubMed Web of Science ®Google Scholar
• TsukadaTFushidaSHaradaSLow-dose paclitaxel modulates tumor fibrosis in gastric cancerInt J Oncol20134241167117423443842
   PubMed Web of Science ®Google Scholar
• ParkHBPaikDJJangEHongSYounJAcquisition of anergic and suppressive activities in transforming growth factor-beta-costimulated CD4+CD25-T cellsInt Immunol20041681203121315237111
   PubMed Web of Science ®Google Scholar
• FantiniMCBeckerCMonteleoneGPalloneFGallePRNeurathMFCutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7J Immunol200417295149515315100250
   PubMed Web of Science ®Google Scholar